Literature DB >> 11875631

Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response.

David Arthur1, Edward D Levin.   

Abstract

RATIONALE: Acute and chronic systemic nicotine administration has been shown to cause significant spatial memory improvement. The critical nicotinic receptor subtypes for this effect and their location are still being determined. Nicotinic receptors in the ventral hippocampus have been found to be critically involved in memory. Acute ventral hippocampal infusions of dihydro-beta-erythroidine (DHbetaE), an alpha4beta2 nicotinic receptor antagonist, impaired spatial memory of rats in the radial-arm maze.
OBJECTIVES: The current study used chronic ventral hippocampal infusion of DHbetaE as a model of nicotinic receptor loss such as that which occurs in Alzheimer's disease. The therapeutic effect of systemic nicotine treatment in reversing the DHbetaE-induced memory impairment was determined.
METHODS: Rats were pretrained to asymptotic levels of performance on the eight-arm radial maze. Then, they were implanted with bilateral infusion cannulae in the ventral hippocampus, through which 0, 33.3, or 100 microg/side/day of DHbetaE was continuously infused for 4 weeks. The rats were retested on the eight-arm maze throughout infusion period and after withdrawal, and the interaction of acute systemic nicotine injections on memory was tested.
RESULTS: The higher (100 microg/side/day) but not the lower (33.3 microg/side/day) DHbetaE dose caused a significant spatial memory impairment. Acute systemic nicotine injections (0, 0.1, 0.2, and 0.4 mg/kg, subcutaneous) attenuated the memory impairing effects of 100 microg/side/day of DHbetaE. There was no significant effect on response latency with the chronic DHbetaE infusion. Acute systemic nicotine infusions did significantly speed responding, an effect which was reversed by chronic hippocampal infusions of DHbetaE. After withdrawal there were no significant lasting effects on choice accuracy or response latency. Wet-dog shakes were significantly elevated during chronic hippocampal DHbetaE administration with no effect during the withdrawal period.
CONCLUSIONS: These results indicate that chronic inhibition of a subset of nicotinic receptors in the hippocampus results in a significant impairment in the spatial memory choice accuracy. The ability of nicotine to attenuate the impairment supports the development of nicotinic agonist therapy of syndromes, such as Alzheimer's disease, that involve a chronic decrease in the activity of the alpha4beta2 nicotinic receptors and memory impairment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11875631     DOI: 10.1007/s00213-001-0961-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.

Authors:  G Dunbar; P H Boeijinga; A Demazières; C Cisterni; R Kuchibhatla; K Wesnes; R Luthringer
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 2.  Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine.

Authors:  Justin W Kenney; Thomas J Gould
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

3.  beta2-Subunit-containing nicotinic acetylcholine receptors are involved in nicotine-induced increases in conditioned reinforcement but not progressive ratio responding for food in C57BL/6 mice.

Authors:  Darlene H Brunzell; Jessica R Chang; Brandon Schneider; Peter Olausson; Jane R Taylor; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2005-08-13       Impact factor: 4.530

4.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

5.  Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus.

Authors:  Jessica M André; Prescott T Leach; Thomas J Gould
Journal:  Neuropharmacology       Date:  2010-12-16       Impact factor: 5.250

6.  Chronic underactivity of medial frontal cortical beta2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats.

Authors:  Edward D Levin; Abigail Perkins; Terrell Brotherton; Melissa Qazi; Chantal Berez; Janitza Montalvo-Ortiz; Kasey Davis; Paul Williams; N Channelle Christopher
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

Review 7.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Improvement of attentional function with antagonism of nicotinic receptors in female rats.

Authors:  Edward D Levin; Marty Cauley; Amir H Rezvani
Journal:  Eur J Pharmacol       Date:  2013-02-08       Impact factor: 4.432

Review 9.  Complex relationships of nicotinic receptor actions and cognitive functions.

Authors:  Edward D Levin
Journal:  Biochem Pharmacol       Date:  2013-08-06       Impact factor: 5.858

10.  Neurotoxicity of FireMaster 550® in zebrafish (Danio rerio): Chronic developmental and acute adolescent exposures.

Authors:  J M Bailey; E D Levin
Journal:  Neurotoxicol Teratol       Date:  2015-07-31       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.